![](https://cdn.sanity.io/images/0vv8moc6/targetedonc/13af1f98f8a3e7efeeba919b26d7168e98879ad5-480x270.jpg?fit=crop&auto=format)
FDA Oks FoundationOne CDx and Liquid CDx for Use With Olaparib/Abiraterone in Prostate Cancer
The FDA has approved the FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for the combination of olaparib (Lynparza) and abiraterone (Zytiga) with prednisone or prednisolone for the treatment of adult patients with BRCA-mutated …